jupiterneurosciences.com (JUNS) - Rasio rega marang prakiraan pendapatan
The projected market cap-to-revenue ratio for Jupiter Neurosciences Inc (JUNS) exhibits volatility, as the business relies on secondary offerings due to a lack of commercial products. Growth potential is driven by AI-powered robotic laboratories for data analysis and a team of high-paid neuroinflammation experts. The value of 41.20 characterizes this valuation metric, indicating the issuer's current stage of development.
Rincian metrik komprehensif lan analitis jupiterneurosciences.com (JUNS)
- rega saham lan target rega konsensus:
- indikator kapitalisasi pasar:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Jupiter Neurosciences Inc|JUNS - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Jupiter Neurosciences|JUNS - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Jupiter Neurosciences Inc|JUNS - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Jupiter Neurosciences|Rasio cepet jupiterneurosciences.com
- rincian asil keuangan lan kelipatan valuasi:
JUNS - Asil keuangan resik|Proyeksi bathi mangsa ngarep Jupiter Neurosciences Inc|JUNS - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Jupiter Neurosciences Inc|JUNS - Rasio P/E diaturake wutah|Pangali EV/EBITDA Jupiter Neurosciences Inc|JUNS - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Jupiter Neurosciences|JUNS - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan jupiterneurosciences.com|JUNS - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Jupiter Neurosciences Inc
- rincian pendapatan lan dodolan:
Analisis wiwitan perusahaan:JUNS (Jupiter Neurosciences Inc)
The forward P/S ratio determines the market value of a business relative to expected sales volume, allowing for an assessment of the premium investors are willing to pay for future cash flows. By analyzing the projected P/S parameter, one can compare the capitalization rates of Jupiter Neurosciences Inc (JUNS) with the commercialization potential of their neurobiological developments aimed at protecting neurons in Alzheimer's and Parkinson's diseases.
Analisis perusahaan pesaing
Biogen - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan NBIX|RGC - Rasio rega marang prakiraan pendapatan|AXSM (Axsome Corp) - Kapitalisasi marang prakiraan pendapatan|ACAD: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep xenon-pharma.com (XENE)|Multiplikator forward rega marang pendapatan VKTX|Multiplikator Forward P/S Supernus Pharmaceuticals, Inc.|Rasio rega marang prakiraan pendapatan Catalyst Pharmaceuticals Inc (CPRX)|DNLI (Denali Corp) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Harmony Biosciences HRMY|biohavenpharma.com (BHVN) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|AMLX - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Trevi Therapeutics Inc TRVI|PRAX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Anavex Life Sciences Corp|CBLL (CeriBell, Inc.) - Multiplikator Forward P/S|Prothena Corporation (PRTA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ALEC|ANNX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Omeros OMER|NGNE: Kapitalisasi marang prakiraan pendapatan|AC Immune - Multiplikator Forward P/S|voyagertherapeutics.com (VYGR) - Multiplikator forward rega marang pendapatan|NMRA: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Scilex Holding (SCLX)|Rasio rega marang prakiraan pendapatan Tevogen Bio Holdings, Inc.|Alpha Cognition Corp (ACOG) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan CGTX (Cognition Therapeutics)|IKT (inhibikase.com) - Rega forward marang dodolan|Multiplikator Forward P/S SAVA (Cassava Sciences)|Rasio kapitalisasi marang dodolan sing dikarepake Assertio Holdings (ASRT)|COYA - Rasio rega marang prakiraan pendapatan|VTGN (Vistagen Therapeutics) - Kapitalisasi marang prakiraan pendapatan|OVID: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan acumenpharm.com|Rasio rega marang prakiraan pendapatan CervoMed|ATHE (Alterity Therapeutics Ltd) - Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan CLNN (Clene Inc.)|Multiplikator Forward P/S pepgen.com (PEPG)|Rasio rega marang prakiraan pendapatan Relmada Therapeutics RLMD|ANVS: Kapitalisasi marang prakiraan pendapatan|GRCE - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Firefly Neuroscience, Inc. AIFF|anewmeds.com (KLTO) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan NRSN|RVPH (Reviva Pharmaceuticals) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep MetaVia, Inc. MTVA|Multiplikator forward rega marang pendapatan NRXS (NeurAxis)|Multiplikator Forward P/S heliusmedical.com (HSDT)|Rasio rega marang prakiraan pendapatan Passage Bio PASG|Rega forward marang dodolan NEUP|NERV - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep athira.com|Addex Therapeutics Ltd (ADXN) - Rasio rega marang prakiraan pendapatan|ALZN: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan CYCN|Multiplikator Forward P/S Protagenic|Rasio rega marang prakiraan pendapatan Pasithea Therapeutics (KTTA)|CRGT: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S ATXI (Avenue Therapeutics, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Brainstorm Cell Therapeutics Inc. (BCLI)|CARA: Multiplikator forward rega marang pendapatan|Chromocell - Rasio rega marang pendapatan sing dikarepake|ELYM: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Intra-Cellular Therapies, Inc. (ITCI)|Rasio rega marang prakiraan pendapatan Longboard Pharmaceuticals, Inc.|MRNS: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan NKGN (NKGen)|NRBO (NeuroBo Pharma) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Sage Therapeutics, Inc. SAGE|SNPX: Kapitalisasi marang prakiraan pendapatan|Trevena - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vigil Neuroscience|WENA (Anew Medical) - Multiplikator forward rega marang pendapatan|Cerevel Corp (CERE) - Multiplikator Forward P/S
